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NetworkThe usefulness of the results so far published on genetics of primary hypertension for establishing the clinical
impact of candidate gene polymorphisms is weakened by the scanty information regarding: a) the functional
effect of the gene variants of interest in humans; b) the regulatory genetic network (RGN) where the gene is
operating with all the interacting environmental–biological factors and the respective hierarchical
organization; c) the consistency between the natural history of the established pathophysiological
mechanisms underlying hypertension and the new molecular mechanism detected with genetics; d) the
limitations regarding the translation of animal data to human due to the differences among species of the
genetic molecular mechanisms underlying similar organ function changes in the different species. Of course,
not all these information are available for adducin polymorphisms. In this review, being aware of their
importance, the evaluation of the clinical impact of adducin has been focused on data obtained together with
the interacting genetic-environmental or biological factors. Adducin polymorphisms and endogenous
ouabain (EO) were detected by a top-down approach in rodents after having demonstrated, at cellular and
kidney level, that an increase in tubular Na reabsorption could underlies the transition from normotension to
hypertension both in rodents and humans. Therefore, we hypothesized that adducin polymorphisms and EO
may operate within the triggering RGN that initiates the increase in blood pressure in both species. The
distinction between triggering RGN and the secondary RGN is important both to limit the level of genetic
complexity arising from secondary changes, and to detect the molecular target to develop tailored
therapeutic approach. The pharmacogenomic approach, both in rodents or humans, with newly discovered
and never treated hypertension, may be useful to strengthen the “causation” of genetic mechanism. Mutant
adducin increases tubular reabsorption: diuretics, because of their effect on overall tubular reabsorption, or
rostafuroxin, because of its selective inhibition of the adducin and ouabain effects, may be used for this
purpose. Indeed the pharmacogenomic approach with both drugs have provided data consistent with the
role of adducin and EO. Taken together, all these ﬁndings indicate a clear impact of adducin polymorphism
and EO in a subset of patients when the appropriate environmental, biological or genetic context is taken
into account. The size of this impact is variable and affected by the context.ulatory genetic network; CV,
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In spite of the considerable technological progress in studying the
relationship between DNA variations and cellular or whole organism
phenotypes in experimental settings, the estimation of the clinical
impact of speciﬁc molecular mechanisms in complex human diseases
remains the major challenge [1,2]. After 20 years of research on
candidate genes in primary arterial hypertension a consensus on their
role has not been reached yet [3,4]. On the other hand, the whole
genome scanning is producing convincing and replicable data support-
ing the involvement of some SNPs, but the effect size of these SNPs (or
the portion of the hereditability that they are able to explain) is very
modest (0.5–3.3 mmHg) [5–9]. Most of the association studies data so
farpublishedonadducinpolymorphismshave the same limitations [10].
Genetic heterogeneity (the same phenotype may be produced by
different genetic mechanisms) and epistasis (modulation by other
genes of the effect of a particular gene) taken together with other
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complexity is also involved in human monogenic disease [11,12]. The
same gene variant within the same family tree may be associated to a
mild clinical symptoms at adult age or to a devastating disease at young
age [11,12]. Certainly, the effect of the gene modiﬁers is magniﬁed in
polygenic multifactorial disease like hypertension. The tendency to
increase the size of the sample to reach an adequate statistical power
cannot replace the requirements arising from the facts mentioned
above. The replications of ﬁndings across different populations are
certainly important; however, the lack of knowledge on the context
difference among these populations limits the validity of this important
criterion. Even in a typical monogenic disease like phenylketonuria the
clinical symptoms are related to the amount of phenylanine in the diet.
The contemporary genetics is developing the concept of genetic–
biological–environmental network to properly handle this genetic
complexity [2,11–17]. Many convincing data have been so for obtained
in experimental settings [18,19]. However, the translation of the animal
data to human clinical symptoms requires the assessment of possible
similarities or differences among the regulatory genetic networks
(RGN) across species [20]. On the other hand the animal model of
complex diseases is indispensable to detect the regulatory RGN by the
top-down approach with the appropriate genetic manipulation,
protein–protein or protein–tissue interactions. Four groups of problems
hamper the capacity of the current genetics strategies to provide
appropriate data to improve the present clinical approaches to primary
hypertension (in terms of etiopathogenesis, diagnosis therapy and
cardiovascular (CV) risk assessment).
1.1. Regulatory genetic networks (RGN) across species and within
species: The comparison with the developmental biology
Recent data on single or double gene inactivation effects revealed
important RGN differences across species [21,22]. Single gene inactiva-
tion seems to produce more consistent effects across species implying
similar gene function [21]. Conversely, double inactivation unmasks
much larger differences across species [21]. Themost likely explanation
for these data is that the network rearrangement after inactivation of
one gene occurs throughoutmolecularmechanismpathways that differ
among species. However, some of these double inactivation effects are
well conserved across species that separated by 1 billion years of
evolution [22,23]. Therefore, there are well conserved networks (core
networks) as well as species-speciﬁc RGNs. The development of a given
level of blood pressure (BP)may be assimilated to the development of a
given organ function. In fact in both settings the cooperation among a
variety of cell lineages, hormones, nervous signals, load and environ-
ment is needed to achieve a speciﬁc level of organ structure and function
or BP. Consequently, the bulk of knowledge on the RGN underlying
organ development may help to understand the RGN in hypertension.
The concept of organ homology across species [24], that is,
similarities of organ function and structures across species, may also
be applied to the approaches aimed at establishing similarities or
differences among RGNs regulating BP across species. Developmental
studies have clearly established that the same organ, structure and
function existing between two species may be achieved by species-
speciﬁc molecular mechanisms [25,26]. Because of the variety of
pleiotropic functional effect of each gene product (or node within the
RGN) the gene functionusedby aparticular organRGNmaydiffer across
species. It is thepeculiarmolecular context of the tissue at thegiven time
of its development that determines the connection among the single
nodeswithin the RGN [26]. This implies that both structure and function
of each gene product or node must be assessed in each species to draw
conclusions about molecular comparison between two species. Within
developmental RGNs there are two types of nodes (or gene products)
[26]. A ﬁrst type can be inactivated without functional alterations,
because they are nodes with low level of connectivity with other nodes.
Conversely, the inactivation of the second types of nodes, that have amuch higher level of connectivity with other nodes, produces much
greater functional consequences. In other words, the functions of the
ﬁrst type of nodes may be buffered by the RGN, while the functions of
the second type are not easily buffered by the RGN.When perturbed by
mutations, these latter nodes, also called “hub proteins,”may produce a
shift or change in the function of RGN. In the literature the genetic
molecular ﬁndings in rodents are frequently translated to humans
without considering the problems illustrated above. The combination
between genetic structure and function is emerging as the most
appropriate approach to unravel the key protein function (or hubs) that
determines the overall RGN function.
1.2. Pathophysiological data
1.2.1. Plasma renin and blood pressure level
In the past, the controversy on the role of plasma renin in the
regulation of BPwas fostered by contrasting levels of BP associatedwith
high plasma renin levels. In fact, high renin levels may be associated
with hypotension, normotension and hypertension. Therefore, the
conclusion was: renin could not be involved in the regulation of BP[27].
The progress of our knowledge on the variety of factors involved in the
BP regulation, and, especially, the availability of the selective inhibitors
of the renin–angiotensin–aldosterone system (RAAS) led us to have a
morebalanced and correct viewon the role of theRAAS [28,29]. This role
must be assessed within the framework or factors involved in the
regulation of body sodium (Na intake and renal Na excretion), body
ﬂuids and other CV functions (cardiac output, peripheral resistance) or
tissue production of the various RAAS components [30,31]. The same
factors affecting theplasma renin–bloodpressure relationshipmust also
be involved in the relationship between RAAS gene variants and BP
level. Theevaluationof the clinical impact of any candidate genemust be
carried out within the appropriate context of the factors, detected with
50 years of pathophysiological studies.
1.2.2. Phases of hypertension
The hypertension triggered by the reduction of renal blood ﬂow
(renal artery constriction) is sustained by a sequence of mechanisms
that start with renal secretion of renin, followed by renal Na retention
and ending with peripheral vascular autoregulation or vascular
remodelling. At this phase structural vascular or organ changes may
take over the initial functional changes [32–40]. Regardless of this
variety of mechanisms, hypertension may be reverted by removing the
renal artery stenosis [41,42]. However, if this manoeuvre is carried out
when the vascular structural changes or renal damage reach a critical
level that confers to them the ability tomaintain hypertension, its effect
on BP is negligible [43]. The time (or phase)-dependent changes of the
various mechanisms supporting hypertension occur in spite of the fact
that a “triggering”mechanism, the renal artery clip maintains the same
degree of artery constriction. The samephase-dependent changes of the
various hypertensive mechanisms occur in rodents with genetic
hypertension [44]. Also in humans, with primary hypertension,
renovascular hypertension or monogenic forms of hypertension there
are data supporting the phase-dependent variations of themechanisms
underlying hypertension or organ damages [45–47]. Therefore, in order
to correctly evaluate the genotype-intermediate phenotype relation-
ship, the phase-dependent changes illustrated above must be take into
consideration the natural history of hypertension (both the initial
triggering mechanism and its secondary ones) [32,45–47].
1.3. Integration between genetic and pathophysiological clinical data
In monogenic forms of hypertension we may have different types
of RGNs. All these forms involve the ability of the kidney to handle Na
and water [48] either as a renal constitutive change (renal RGN) [49]
or secondary kidney change triggered by an increased production of
adrenal endogenous substances, aldosterone or other mineral
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In these hypertensive forms, the characteristic of being “triggering”
RGN is conferred by a highly penetrant genetic mutation affecting
either Na channel endocytosis [49] (Liddle syndrome) or the steroid
synthetic pathway [48]. This latter alteration, with or without the
neoplastic growth, is responsible for a variety of adrenal forms of
hypertension. In the past, through pathophysiological and genetic
tools, the triggering RGNs (or gene variants or hormones) were
identiﬁed and provided the rationale for a “causal antihypertensive
therapy” (spironolactone or eplerenone) for the hyperaldosteronism
(within themineral corticoids forms of hypertension) or amiloride for
the Liddle syndrome. It is important to realize that also the triggering
RGN approach implies that the same gene variant may produce
hypertension across a variety of combinations with other gene
variants according to the peculiar individual RGN in which the gene
of interest must interact within the different tissues or species. A gene
variant favouring Na transport in the renal ascending limb may be a
primary cause of hypertension if it is associated to some of the
following different abnormalities regarding both:
a) a compensatorymechanism such as a decrease of Na reabsorption in
the more distal part of the nephron or inhibition of the tubulo-
glomerular feed back mechanism [51] that, in turn, may have a
variety of molecular mechanisms [52]: 1) Na and Ca transport
systems across the luminal membrane of themacula densa; 2) renin
release [53]; 3) afferent arteriolar tone etc;
b) the mechanisms regulating the relationship between extracellular
volume and BP. For instance, a genetic mechanism that activates the
Na–K pump at the basolateral membrane of tubular cell may favour
Na retention and expansion of body Na. But this alteration should be
coupled with a mechanism that prevent vascular dilatation at the
kidneys or at the whole organism levels or even increase vascular
tone. The combination of these two types of mechanisms may
represent a triggering RGN [54]. Mutated adducin and endogenous
ouabain (EO) may well trigger hypertension throughout a combi-
nation of renal and vascular effect (see below).
As suggested by the genetics of organ developmental studies a
speciﬁc genetic variant may also inﬂuence more than one of these
individualmolecularmechanisms [26] (pleiotropic effect) in such away
tomodulate their actions towards an increase of BP. Therefore, from the
pathophysiological perspective, the RGN may be composed by a
complex and variable set of gene variants that may change from a
subset of patients to another one. Most of the RGN approaches have
been developed with single pathological tissues in human or in others
species. Pathophysiological data discussed above demonstrate the
cooperation among different tissues (kidney, adrenal, vessels, etc.)
during the initial phase. Therefore, the concept of triggering RGN beside
the protein–protein interactionwithin a deﬁned tissuemay also include
the interactions among relevant molecular mechanisms from different
tissues. Again, similarities with the RGN underlying organ development
may be found: the statement “complex traits are spatio-temporal
collectives of multiple interacting gene products” [55] summarizing the
contemporary RGN approach to organ development, may also be
applied to arterial hypertension. For RGNs involved in hypertension we
should only change spatio-temporal with organ-temporal.
1.4. Translation of animal data to human
As it has been suggested for the organ development, also for the
genetics of phase-dependent hypertension illustrated above, we may
hypothesize that the RGNs are hierarchical [24,54]. There may be a
portion of “core” or “triggering” RGNs controlling the initial stages of
hypertension that is at the top of the hierarchy. These RGNs may be
considered also as the core triggering RGNs present in all species (like
the renal artery constriction that triggers hypertension across
different species including human). Then we may have a portion of“secondary” RGNs controlling intermediate phenotypes (renin, body
sodium, Na+ intake, etc.) staying in the middle. Finally, we have a
portion of RGNs controlling the detailed functions of cells in different
organs that are at the periphery or at the bottom of the hierarchy.
These RGNs may be involved in vascular remodelling and organ
damage. Moving from the top (core or triggering RGNs) to the bottom
RGNs, the differences across species may increase. Therefore, trans-
lational studies should be more efﬁcient and productive if developed
at the level of a core triggering RGN that can only be detected by
studying the initial development of hypertension within a normo-
tensive population or background.
This distinction may have therapeutic implications, as discussed
above for renovascular hypertension. The deﬁnition of the core or
triggering networks is also relevant to detect the molecular targets to
develop the most appropriate “causal” therapies. The BP responsive-
ness to drugs in experimental renovascular hypertension may vary
across the different phases [56–60]. RAAS inhibitors are particularly
active in the I phase, diuretics or reduction of Na intake is needed in
the II phase, while Ca2+ antagonists may be needed to lower BP when
an important vascular remodelling is present. A drug active on the
triggering mechanisms (in this case an hypothetical drug that acts as
the removal of artery constriction)may have amore stable and a long-
lasting effect provided if it is used before the development of severe
CV or renal secondary change. Moreover, with this hypothetical drug,
the compensatory mechanisms trying to bring the BP to the original
high level are less likely to occur [61]. It is noteworthy that J.O. Davis
[40] in his review on renovascular hypertension deﬁnes this condition
“a multifactorial disease” because of the many mechanisms triggered
by the clip on the renal artery. However, the removal of the clip is
followed by “normalization” of BP and all the other factors, if this
manoeuvre is carried out before the appearance of overt organ
damage. Therefore, this effect of unclipping may support a deﬁnition
of a “monofactorial disease” cured by a single manoeuvre. Similarly,
the inhibition of initial triggering network in the appropriate subset of
new discovered hypertensive patients may block the effects of many
secondary genetic changes, resulting in long-lasting normalization of
BP. Also, in two other forms of hypertension where the primary cause
is known such as primary hyperaldosteronism or Liddle syndrome,
the clinical practice has demonstrated that the speciﬁc drug
spironolactone or amiloride, are able to normalize BP only when
administrated before the development of secondary organ changes.
On the contrary, these drugs would be less effective if administered in
patients with long-lasting hypertension (O. Melander, personal
communication).
The Mendelian randomization has been proposed [62–64] to
strengthen the detection of a causal relationship between gene
variations, intermediate phenotypes and the associated organ
damages, including the effects of drugs. This approach is certainly
appropriate for those intermediate phenotypes, such as plasma levels
of cholesterol or lipoproteins that are relatively stable across the
different stages of the disease and are more directly related to the
genetic abnormalities or mutations [63]. However, the phase-
dependent changes in hypertension weaken the scientiﬁc validity of
any negative ﬁnding obtained with Mendelian randomization if the
time-course of the disease is not taken into account. Very advanced
technological approaches to measure the overall gene variation or
statistical sophistication, taken alone, are unable to capture this
complexity. The challenge of the genetics of primary hypertension is
to detect this core or triggering RGN with its hubs or major effect
gene products both in the lab animalmodel (rodents) and in humans.
This may lead to the subdivision of this heterogeneous human
condition into deﬁned subsets of patients relatively more homoge-
neous for the respective core RGN, clinical characteristics (type of
organ damage) and long-lasting response to a selective drug hitting
the hub nodes within the core triggering RGN. In our view this
triggering RGN may provide the compass or “marker” (similar to a
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as to deﬁne new nosological clinical entities in this era of molecular
medicine.
2. Adducin
2.1. Detection of adducin as a candidate gene
To what extent do the adducin and EO data so far available in
rodents and humans may support the hypothesis that they could
function as “hub node(s)” within the above described triggering core
RGN at work in both species? Clearly, our studies aimed at detecting
molecular mechanisms of primary hypertension triggering a transi-
tion from normotension to hypertension started many years ago
before the genetic era. The various steps of these studies leading to the
identiﬁcation of a genetic mechanism described in detail elsewhere
[10] may be summarized as follow:
1) development of a rat model of primary hypertension (the Milan
normotensive rats (MNS) and the Milan hypertensive rats (MHS)
strains) and assessment of possible similarities or differences
between rodents and humans. This assessment was carried out at
different levels of biological organisation: whole organisms, kidney
function, plasma levels of hormones and cellular function. Only
prehypertensive and early hypertensive stages were considered on
the “obvious” assumption that these stages are themost appropriate
to detect initial pathophysiological triggering mechanisms;
2) these studies demonstrated that the pathophysiological abnor-
malities responsible for triggering hypertension in rat could also
be at work in a subset of patients;
3) the bulk of data were consistent with the hypothesis that a
primary abnormality, within the kidney could be the triggering
mechanisms. This hypothesis was strengthened by the observation
that hypertension may “travel” with the transplanted kidney in
both species;
4) moving from the rat whole kidney function down to nephron
segmental function, the data obtained were consistent with the
hypothesis that a primary increase in tubular reabsorption
(particularly at the proximal level) could be considered as the
primary mechanisms;
5) proximal tubular cells of young prehypertensive rats were smaller
and had lower Na content and faster membrane Na transport.
Similar changes were present in erythrocytes; therefore, a
generalized genetic abnormality could be envisaged;
6) through bonemarrow transplantation betweenMHS andMNS rats
we demonstrated that these changes of erythrocytes were
genetically determined within the stem cells. Therefore, erythro-
cyte ion transport could be used to assess similarities or
differences between humans and rats;
7) the differences in rat erythrocytes ion transport were still present
in resealed ghost (still having the membrane actin cytoskeleton)
but absent inside vesicles (devoid of the actin of cytoskeleton);
8) actin cytoskeleton fromMHSwas injected into MNS and vice versa
in order to detect immunological differences between the
cytoskeleton proteins at the two strains;
9) an antibody towards a cytoskeleton protein was detected and used
to screen a DNA library. Adducin was detected in this way.
Therefore, adducin was detected after a long series of studies
focused on the triggering pathophysiological mechanisms at work in
rats and humans.
Certainly, this strategy differs from that used to develop the
contemporary concept of RGN. However, the nine groups of data
mentioned above provide the theoretical and experimental support to
the notion that adducin polymorphism is involved in a core triggering
RGN. The mutations in rodent and human adducin occurred at
different position in the two species [10] (see Fig. 1). It has beenpreviously shown that the different lactase gene alleles in African
population of different ancestries have similar function [65]. Similarly,
mutated adducin of both species produce similar modiﬁcations of the
protein functions, that is, both stimulate renal Na transport by
activating the Na–K pump on the basolateral membrane [10] and
produce a greater activation of the Na–K pump-dependent signal
transduction (M. Ferrandi and P. Ferrari, personal communication).
Simultaneously, studies on EO (see also the chapter of P. Manunta)
revealed very interesting interrelationships with the adducin poly-
morphism. Ouabain modulates the Na–K pump activity in a
concentration-dependent manner [66,67]: activating the renal Na–K
pump at subnanomolar concentrations, leading to increased renal Na
reabsorption, or inhibiting it at slightly higher concentrations, thus
favouring renal Na excretion. Moreover, this low concentration EO is
also able to increase the vascular tone [68].
Higher levels of plasma EO potentiate the difference in the pressor
response to saline infusion between carriers of mutated Trp allele in
Adducin 1 (ADD1) gene and in carriers of the wild type allele (rs4961)
[69]. This action occurs through a vascular effect because no
modiﬁcation of renal Na excretion was detected. The molecular basis
of this vascular effect is not entirely known even though theNa–Kpump
activity modiﬁcation is the likely mechanism. From the pathophysio-
logical viewpoint, the relationship between EO and adducin resembles
theonebetween aldosteroneandNa channel on the luminalmembrane.
Both the hormones may adjust the function of the constitutive capacity
of tubular cells to transport Na according to the body need. The renal
target of aldosterone is theNa channel,while the renal target of EO is the
Na–Kpumpthat, in turn, ismodulated byadducinpolymorphism. Either
mutated adducin or EO may be important components of a core
triggeringRGNatwork in the subset of patients carrying the appropriate
mutations of the genes coding for adducin or for the enzyme involved in
EO synthesis transport or excretion affecting the renal Na transport and
vascular tone. This hypothesis is markedly reinforced by the demon-
stration that the selective inhibitors of these twomechanisms in rodents
also normalize BP in the subset of patients carrying the mutations
mentioned above (M. Ferrandi, P. Ferrari andG. Valentini, manuscript in
preparation).
The results so far available on the relationship between adducin
polymorphisms and the various human phenotypes, somehow
connected to hypertension and its CV complications, have been
collected as follow:
a) association studies between ADD1 or adducin 2 (ADD2) genes
alone and presence or absence of hypertension or BP levels
subdivided according to the most studied populations: Caucasian,
Chinese and Japanese;
b) studies considering interactions between ADD1 and ADD2 or
adducin 3 (ADD3) genes or between ADD1 and RAAS genes or
other genes coding for protein regulating body Na or increasing
vascular tone, such EO and WNK lysine deﬁcient protein kinase 1
(WNK1), neural precursor cell expressed, developmentally down-
regulated 4-like (NEDD4L) genes [70]. The interactions among
ADD1, ADD2 and ADD3 have to be studied because the genes
coding for these proteins map on different chromosomes, but the
proteins are working together within the cells as dimer or
tetramer (ADD1/ADD2 or ADD1/ADD3). Because of these bio-
chemical characteristics, a genetic interaction among the adducin
loci provides an additional argument to support the link between
the adducin polymorphisms and the phenotype of interest.
Adducin polymorphism affects the constitutive capacity of renal
tubular cell to reabsorb Na, thus it inﬂuences BP throughout
variations on total body sodium [10,71–74]. Therefore, beside the
Na intake, any evaluation of the effect of adducin polymorphism
on BP must also consider the polymorphism of genes coding for
the proteins involved in the activity of the RAAS, EO or other
proteins involved in the regulation of renal Na handling or vascular
Fig. 1. ADD1, ADD2, ADD3 gene structure and relative adducin protein structure. a) Adducin genes are indicated by boxes; black ﬁlled box indicates alternative spliced exons in
ADD2-β4 isoform. The position of SNPs is shown by the arrows with the SNP coordinates based on the aminoacid change for only missense mutations. The human SNPs are typed in
regular and also report dbSNP ID in brackets while the rat ones are in italics. The human and rat chromosome location is reported on the left. b) Single subunit and dimer/tetramer
structure of adducin protein. In the cell adducin works as a dimer (ADD1/ADD2 or ADD1/ADD3) or as a tetramer. Therefore, this provides the biochemical base for the genetic
interaction among the various adducin loci.
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have demonstrated the importance of the interaction between
body Na and RAAS in the regulation of BP and CV complications.
c) the combination of the genotyping data with the BP lowering
effect of diuretics or of another drug that selectively affects
mutated adducin or EO effects has also be studied. These
pharmacogenomic approaches not only may provide useful
information for administering the right drug to the right patients
but may also provide a strong additional argument to support the
clinical impact of these genetic mechanisms.
In the article published in 2005 [10], the various aspects of the
adducin polymorphisms spanning from basic science to clinical
application were reviewed. The present review discusses the results
from clinical studies published during the last 4 years.
2.2. Association studies in Asian populations
According to a PubMed search covering the period from our review
article published in 2005 [10] to the end of 2009, 59 additional articles
have been published on the role of adducins in various clinical setting.
However, considering the studies measuring only the ADD1 Trp allele
frequency in normotensives and hypertensives (association study) the
proportionof positive andnegativeﬁndingswerenot different fromthat
reported in 2005. Therefore, it may be concluded that mixed results are
obtained when the frequency ADD1 Trp allele is considered alone. The
many ﬂaws of these studies (in terms of deﬁnition of normotension,
collection of data, admixture of confounding factors), taken together
with the lack of a proper deﬁnition of the context, weaken the scientiﬁc
validity of these data. Already in 1999 [75] we demonstrated that the
frequency of theADD1Trp allele in hypertensives could be either higher
or similar to that of normotensives in two Italian populations. Also the
arguments, developed in the previous section, clearly suggest that only
the ﬁndings at b) and c) are relevant to evaluate the clinical impact of
adducin polymorphisms. However, some comments on the association
studies carried out in Asian populations may be of interest because the
frequency of the ADD1 Trp allele is almost three times higher compared
toCaucasians (48%vs. 17%) (NCBI dbSNP site http://www.ncbi.nlm.nih.
gov/SNP/snp_ref.cgi?rs=rs4961). So far 14 studies have been carried
out in the Chinese populations. Three studies [76–78] reportedgenotyping of DNA markers mapping around the ADD1 locus but
separated by many haplotype blocks [10]. Therefore, these negative
ﬁndings arenot relevant to evaluate the role of adducin. Four association
studies genotyping the ADD1 Trp allele [79–82] are positive (in one of
these studies [81] also the familial quantitative transmission disequi-
librium test (QTDT) was positive), two studies [83,84] provided
negative data. Other positive studies included one study [85] showing
an interaction of the Trp allele with the I/D polymorphism of
angiotensin-converting enzyme gene (ACE) on systolic BP and in the
family-basedQTDTanalysis. Other two studies showed an association of
the Trp allelewith intracerebral hemorrhage [86] orwith themagnitude
of the BP fall with diuretic [87]. A further study [88] examined different
SNPs on the ADD1 gene and detected a very signiﬁcant SNP
(rs17833172) with a rather low minor allele frequency (4%) but not
the Trp allele SNP (rs4961). Finally, a study applying a structural
equation modelling (SEM) to capture the independent and combined
effect of several genotypes (including ADD1) on renal function of 1188
type 2 diabetic patients was recently published [89]. ADD1, natriuretic
peptide precursor A (NPPA), guanine nucleotide binding protein
(G protein), beta polypeptide 3 (GNB3) and sodium channel, non-
voltage-gated 1 alpha (SCNN1A) genes were found to have an effect on
BP that inﬂuenced renal function.
Ten studies were carried out in Japanese and Korean populations,
two [90,91]with negative results and eightwith positive data. The latter
subset of studies included four studies [92–95] considering only the
single ADD1 Trp allele. One study [95] showed an increase risk to
develop hypertension in carriers to ADD1 Trp allele. Other studies
consideredNaexcretion [96], lowplasma renin levels [97] or interaction
with angiotensinogen (AGT) [98] or with ACE I/D on the decay of renal
function in immunoglobulin class A (IgA) nephropathy [99]. A recent
study [100] examined the possible association with hypertension of a
larger number of SNPs. A SNP (rs3755351) on ADD2 reached high level
signiﬁcance that failed to persist after Bonferroni correction. ADD1
polymorphism is not mentioned in this study, likely because it did not
reach the threshold level of signiﬁcance. Unfortunately, the interaction
between ADD1 and ADD2 has not been analyzed. It is noteworthy that
the twoSNPsonADD2andADD3 found inCaucasianpopulation (rs4984
and rs3731566) have not been detected or detected at a very low
frequency (ADD2 0.03–0.006) in two Chinese populations [101].
Whether Asian populations have different ADD2 or ADD3 alleles, with
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established but it is very likely. For instance the different African
populations from different ancestry have different lactose alleles with
similar function [65]. A recentmetaanalysis carried out byNiu et al. [83]
in 15 association studies, selected from a total of 91 studies found in
PubMed, concluded that there was no difference of the ADD1 Trp allele
between hypertensives and normotensives. The criteria of selection of
these 15 studies (seven in Caucasians and eight in Asian populations)
are not entirely clear. In particular, it is not clear why with so selective
criteria, two studies [93,102] have been included among the negative
ones, while they were considered by the authors to be the positive. The
study of Wang [102] was carried out in a Flemish Caucasian general
population. A similar frequency of Trp allele in hypertensives and
normotensiveswas found, but the age of the population ranged from 10
to 84 years. Therefore,most of the normotensiveswere below the age of
50 years that is usually considered the lowest level of age that allows to
exclude the development of hypertension. In the past, we and others
used much older levels of age to classify as normotensives the controls
used in the association studies to avoid the inclusionof subjects thatwill
develop hypertension later in their life. In this paper themost signiﬁcant
ﬁnding was the interaction between ADD1 Trp allele and ADD2 T allele
(rs4984) in determining the level of BP and the risk to develop
hypertension in women. In the other study [93] the small and not
signiﬁcant difference in the Trp allele between hypertensives and
normotensives was accompanied by both a positive association of the
ADD1 Trp/Trp genotype with hypertension that remains signiﬁcant
after adjusting for various confounders and in nuclear families a
signiﬁcant transmission of the Trp allele to the affected subjects. As
mentioned above, in 1999 [75] we showed that the association study
based on the difference in the Trp allele frequencies between
hypertensives and normotensives may provide positive or negative
results in two different Italian populations. However, gene structure–
function interactions measured as the BP response to diuretics in the
hypertensives of both populations provided more constant results.
Carriers of ADD1 Trp allele, compared to carriers of the ADD1 Gly/Gly
wild genotype, have a larger BP response to diuretics in both
populations. Since then genetics of complex diseases has made some
progress and the limitations of association study based on allele
frequency have been widely recognized. Apparently, our [75] and
other [103–106] efforts along this direction during the last 10 years
were unable to convince some investigators of genetics of hypertension.
In summary, according to present knowledge the studies of Asian
populations on adducin are all positive when some type of interactions
was considered. Studies measuring the difference in frequency of the
Trp allele between hypertensives and normotensives yielded a positive
result only in 8 out of 12. In evaluating the positive results in these two
populationswemust also consider the publications bias that it is always
difﬁcult to assess. However, these data are strong enough to justify
appropriate efforts along the direction we are suggesting in this review
to evaluate the contribution of adducin polymorphisms and EO to the
RGN triggering hypertension in these populations.
2.3. Genetic studies considering the context (risk to develop hypertension)
In order to limit the confounding effect of the population context
and of the various experimental designs, we shall discuss together the
results obtained by the Staessen's group in Belgium and by other
groups in Netherlands.
The Staessen's group, in collaboration with us, has so far published
16 papers dealing with ADD1 alone or in interaction with the other
adducin or RAAS genes or with dietary salt. These studies have been
carried out on two populations:
a) the Flemish study consists of a random sample of the households
living in a deﬁnite area of Northern Belgium followed for several
years;b) the European Project on Genes in Hypertension (EPOGH) study,
including an European family-based epidemiological survey
involving several European countries.
The very high precision of phenotyping and the attempt to deﬁne
either the genetic or the environmental contexts are the main
characteristic of these studies. Some of these results have been
already discussed in the previous review; however, they are recalled
here to provide a more complete picture of speciﬁc aspects.
2.3.1. Interaction of ADD1 with RAAS genes
In the cross-sectional analysis of the Flemish population [107], the
ADD1 Trp allele, per se, or in associationwith the ACE I/D genotypes has
no inﬂuence on BP. Conversely, the effects of ADD1 Trp allele effects on
BP and on the risk to develop hypertension (follow up study) vary
according to the presence of the Aldosterone synthase (CYP11B2) CT+
TT or CC genotypes. In the presence of the CT+TT genotypes, the ADD1
Trp allele is associated with a decrease in systolic–diastolic BP and with
the smallest relative risk to develop hypertension compared with the
whole population. On the contrary, this risk was raised in carriers of
CYP11B2 TT genotypes, while CYP11B2 genotypes taken alone have no
effect. In carriers of ACE DD compared to the other two ACE genotypes
the incidence of hypertension is increased. However, this ACE DD effect
is conﬁned to carriers of ADD1 Trp allele or CYP11B2 CC genotype. The
positive predictive value of the combination of these three genotypes is
40.1%. Carriers of ACE DD and ADD1 Trp allele tend to have an high 24
h urinary Na excretion (196±8mmol/day) comparedwith the carriers
of the other genotypes (176±5 mmol/day) p=0.03. This implies a
difference in Na intake. Parallel renal function studies in the Flemish
population [108] (serum creatinine and urinary protein excretion in
cross-sectional and follow up studies) provided consistent results with
the development of hypertension. In fact the faster decline in renal
function with age (with increased urine protein excretion) occurred in
carriers of both the ACE D allele and ADD1 Trp alleles. The interaction
between ACE and CYP11B2 on renal function was much less clear than
that betweenACEandADD1. A very similar study [85]was carried out in
a Han Chinese population involving 479 participants [108]. This study
conﬁrmed that in the carriers of the ACE D allele and ADD1 Trp
genotypes, the level of BP was higher than in the carriers of other
genotypes. This interaction between ACE and ADD1was also present in
family-basedQTDTanalysis. Only in the adducin Trp allele homozygotes
offspring, the transmission of the ACE D allele was associated to an
increase in BP. Moreover, only in the presence of the ADD1 Trp allele a
signiﬁcant interaction was found between the ACE genotype and
urinary Na excretion in relation to plasma renin activity.
The inﬂuence of Trp allele on the arterial properties (femoral, carotid
andbrachial) of the Flemishpopulationwasalso studied [109–112] both
at a single gene level and in interaction with ACE I/D or AGT or
angiotensin II receptor, type 1 (AGTR1). Again single gene effects were
absent for ADD1 and CYP11B2 but present (although very modest on
intima-media thickness) with ACE I/D only in femoral artery, but not in
carotid artery. This effect was conﬁned to carriers of the ADD1 Trp allele
or the CYP11B2 T allele [109]. Family QTDT studies provided similar
results. Cross-sectional compliance of carotid artery but not that of
femoral artery decreased (compared with the population means) with
the number of ACE D alleles [109]. No effect of ADD1 and CYP11B2
genotypes was detected on cross-sectional compliance and distensibil-
ity of carotid and femoral artery. Compared with the population mean,
carriers of the ACE DD showed a decrease of cross-sectional compliance
and distensibility (but not of diameters) of femoral artery in ADD1 Gly/
Gly genotype. Conversely, in ACE DD carriers the distensibility
coefﬁcient and the diameter of the carotid artery were lower or higher
respectively compared with the population mean. Interaction between
ADD1 Trp and AGT C532T/G-6A or AGTR1 A1166C, including also
brachial artery [111], provided not signiﬁcant results in single gene
analysis with the exception of a slightly larger brachial diameter in
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higher femoral cross-sectional compliance and distensibility in AGTR1 C
allele carriers were conﬁned only to Trp carriers. This effect on femoral
distensibility was also found in family-based QTDT. A similar trend (not
statistically signiﬁcant, p=0.11) was detected for femoral cross-
sectional compliance. The AGT polymorphism alone affects brachial
diameter and distensibility but not femoral or carotid properties and
does not interact with ADD1 on any of the three arteries [111].
2.3.2. Interaction between ADD1 and ADD3
ADD3 genotypes alone affect brachial diameter, distensibility and
cross-sectional compliance, the ﬁrst is lower and the other two are
higher in ADD3 IVS11+386 GG vs. AA (rs3731566). This effect is
conﬁned to ADD1 Gly/Gly carriers and is blunted in ADD1 Trp allele
carriers [111]. No genetic effect was detected on femoral or carotid
artery by ADD3 or by ADD1 and ADD3 on the three arteries. The effect
on brachial artery of ADD3 polymorphismwas conﬁrmedwith family-
based QTDT [111]. Below the age of 50 years the cardiac lateral Ea and
the Ea/Aa ratio (indexes of diastolic relaxation) were higher in ADD1
Trp allele carriers particularly in presence of the ADD3 GG
homozygotes [113]. In older subjects these associations were not
signiﬁcant. The transmission of the Trp allele to offspring (family-
based QTDT) was associated with higher lateral Ea/Aa ratio [113] in
ADD3 GG carriers. The interaction between ADD1 and ADD3, in
EPOGH [114] included three populations (Belgium, Czech Republic
and Poland) that were pooled together because no heterogeneity
across countries was found. No effect of the single genewas found, but
only in carriers of the ADD1 Trp allele the ADD3 GG carriers have an
increased peripheral and central pressure and a tendency to a lower
urinary aldosterone excretion. Conversely, in the ADD1 Gly/Gly
carriers no inﬂuence of ADD3 genotypes in BP was detected, but
subjects with ADD3 GG genotype have a lower urinary Aldosterone.
Family study conﬁrmed the effect of ADD3 GG genotype. This increase
in diastolic relaxation detected only at a relatively young age may be
consistent with an expansion of blood volume at the initial stage of a
type of hypertension triggered by renal Na retention. In fact the slope
of the pressure-natriuresis curve after saline infusion is consistent
with increased renal sodium retention in carriers of ADD1 Trp and
ADD3 GG genotypes (C. Lanzani and P. Manunta, personal commu-
nication). However, other mechanisms are possible. No interaction
between ADD1 and ADD2 on pulse pressure was detected.
2.3.3. Interaction between ADD1 and ADD2
In women only the ADD2 1797T (rs4984) allele was associatedwith
an increased risk to develop hypertension in Flemish population. This
was conﬁned to postmenopausal women and users of oral contra-
ceptives. In men the plasma renin activity (PRA) and 24 h aldosterone
values were lower in ADD2 T allele carriers. There is a signiﬁcant
interactionwith ADD1 Trp allele: the abovementioned effect of ADD2 T
allele was conﬁned to women carrying the ADD1 Trp allele [102]. In the
EPOGH study the Na excretion across the different European countries
was included in the analysis of the relationship between adducin (or
other genes) polymorphism and the phenotypes mentioned above
[115]. Slavic population with high urinary Na excretion compared to
Italian population, have a lower frequency of the ADD2 T allele.
However, the association between this allele and 24 h systolic BP in the
Slavic was not found in the Italian populations [116,117]. In both
populations renal Na excretion was lower in T allele carriers than in the
wild type allele carriers (CC homozygotes), implying some inﬂuence of
the T allele onNa intake. The effect of the T allele on BP andNa excretion
was conﬁrmed by family-based QTDT.
2.3.4. Interaction between adducin and endogenous ouabain (EO)
A long list of experimental and clinical data supports the notion
that EO may affect BP and renal Na excretion through the modulation
of the Na–K pump either as a Na transport system or a signaltransduction triggering mechanism in renal tubular cell or in vascular
smooth muscle cells [66–69,118]. Mutated adducin affects these two
functions of Na–K ATPase. Therefore, it is reasonable to study the
interaction between adducin and EO. When the population of never
treated and newly discovered hypertensive patients were subdivided
into two subgroups, i.e. above and below the median values of plasma
EO levels, only in the former subgroup a clear cut difference in the BP
response to i.v. saline load was found between mutated ADD1 Trp
allele carriers andwild type Gly/Gly ADD1 carriers (+6.75±1.23 mm
Hg and +1.61±0.88 mm Hg, respectively) [69]. In presence of the
mutated ADD1 Trp allele the plasma EO apparently increased in a
predominantly normotensive population [119] or unchanged in new
discovered and never treated essential hypertensive patients [69]. The
reason for this discrepancy is not clear. Certainly, these interrelation-
ship between EO and mutated adducin both at the Na–K pump and at
the whole organism level are consistent with the notion that these
two mechanisms are involved in the body sodium and BP regulation
mainly throughout the modulation of the renal and vascular Na–K
pump as mentioned above.
In the general population the ADD1 Trp allele does not affect the
CV risk. However, when the level of BP is considered, this allele
increases the CV risk in hypertensives and decreases the risk in
normotensives [120] (Fig. 2). It is evident that the clinical symptoms
associated to the mutated allele can be either on the right or on the
left of the wild type carriers as shown in Fig. 3. Therefore, the classical
genetic paradigm developed in monogenic diseases must be revisited
for polygenic multifactorial diseases, where the same “culprit” allele
also may be protective in a peculiar context.
When in the analysis the Trp allele effect is combined with that of
the ACE DD genotype [121] an increase in CV risk is detected also in
the general population. The demonstration of a higher membrane-
bound ACE activity in ﬁbroblasts removed from carriers of the ADD1
Trp allele may provide the cellular base of the association between
ACE DD genotypes and ADD1 Trp allele on CV risk [121].
The attempt to accommodate the ﬁndings of the Staessen group
with other previous ﬁndings within a comprehensive scientiﬁc is
hampered by the difﬁculties to handle two layers of complexity:
1) the complexity of the pathophysiological data so far accumulated
on the mechanisms triggering and sustaining hypertension in the
different phases of hypertension, with the interrelationship among
different tissues and regulatory systems;
2) the complexity underlying the cellular biochemical events at the
single tissue level affected by the genetic mechanisms considered
in these studies that may vary among the various type of cells
(vascular, tubular or cardiac cells) involved in the core triggering
RGN.
With these provisos, the Staessen clinical and epidemiological data
may be reconciled with previous ﬁndings [10] by postulating an initial
increase of renal sodium retention promoted by the interacting effects
of adducin Trp allele, RAAS and EO. The secondary increase of blood
volume and peripheral blood ﬂow, in combinationwith others factors,
particularly the increase in vascular tone (produced by EO), may
trigger other structural CV changes on femoral artery and cardiac
structure and function (diastolic relaxation). At present, it is not
possible to dissect in humans the precise molecular mechanism of
these sequential changes in each type of artery. Either physical factors
(volume, blood ﬂow, hydrostatic pressure, stretching etc.) or
biochemical events (signal transduction or other humoral factors)
may be involved.
In our opinion, the most clinically relevant contribution concerns
the risk of hypertension and organ damage assessed within a deﬁned
epidemiological context. The increased CV risk may be the conse-
quence of either an increase of body sodium [122,123] or of BP which,
per se, may lead to organ damage [124]. Also the ability of RAAS, EO or
Fig. 2. Hazard ratios for total mortality (a) and all CV complications (b) in ADD1 Trp allele carriers relative to Gly/Gly homozygotes as a function of systolic BP at baseline. The
continuous risk function with 95% conﬁdence limits and the P values for interaction (Pint) were computed by multiple Cox regression.
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transduction and ion transport may favour both vascular remodelling
[66,67,125] (M. Ferrandi, manuscript in preparation) and cardiac
diastolic relaxation. In this respect, differences among populations or
among subgroups of patients may be anticipated rather than
surprising. Molecular and statistical sophistication are not adequate
to cope with this complexity without the appropriate data.2.4. Adducin polymorphisms and cardiovascular risk
A total of 14 articles discuss data regarding the possible effect of
adducin polymorphisms on the CV risk, including stroke, coronaryFig. 3. Flowchart of the interaction of genetic and environmental backgrounds and biological
derived from monogenic diseases. Right: two hypothetical populations carrying the “wild typ
progressive increase of the inﬂuence of various factors (left), the distribution of the values
symptom. Therefore, at this highest level of organization, the separation of the two populati
carriers of mutant adducin may even be at the left of the distribution observed in homozyg
environmental or biological contexts as shown in Fig. 2.heart disease (CHD), ischemic heart disease (IHD), myocardial
infarction (MI). These studies have been carried out in:
a) predominantly, normotensive populations where the development
of CV events may or may not be preceded by the development of
hypertension;
b) predominantly, normotensive populations with the distinction
between the CV events developing in normotensive and those
developing in hypertensive patients;
c) studies where subset of patients with and without hypertension
and CV events are compared.
Including the articles already mentioned, 10 independent studies
[120,126–134] evaluated the CV risk in hypertensives and showed thatfactors on the sequence of events linking a DNA variation to a clinical symptom, mainly
e” (dark grey) and the “mutated” (light grey) gene variant are reported. Because of the
of the two populations tends to overlap as we move from the DNA level to the clinical
ons is very modest. As explained in the text, the distribution of the clinical symptoms of
otes for the wild type allele. That is, the mutated allele may be “protective” in speciﬁc
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This increase of risk (OR or RR) ranged from 1.36 to 6 according to the
different population subsets or biological characteristics. It is important
to recognize that in the carriers ADD1 Trp allele and ACE DD genotypes
one ﬁnds:
1) an increased risk to develop hypertension in a general population
of Caucasian [107] and Chinese [85];
2) an increased CV risk either of CV events [121] or of arterial
modiﬁcation that may lead to CV events [110];
3) a faster decline of renal function with age associated to increased
urinary protein excretion [108].
There are also data showing a protective effect of the Trp ADD1
allele in normotensives. In four studies the Trp allele increased the CV
risk in hypertensives but not in normotensives [120,126,127,132].
Four Dutch studies were carried out on a primary care population
aimed at assessing CV risk (Hippocrates Project). Two studies
[135,136] addressed the relationship between ADD1 Gly/Trp poly-
morphism or other genes on arterial stiffness [135] or carotid intima-
media thickness (CIMT) [136]. The only effect of ADD1 detected was a
reduction of CIMT in women carrying the Trp allele. The two others
studies evaluated potential inﬂuence of ADD1 Gly460Trp on CV risk.
The frequencies of the ADD1 allele together with that of other alleles
of 5 genes [137,138] were compared between two population subsets
deﬁned as high or low risk populations. The frequencies of Trp allele of
ADD1 and the T allele of AGT (M235T) were lower in the high risk
group; therefore, they were considered as protective. Also Tobin [139]
found similar ADD1 data when compared patients surviving a MI with
a control population without analyzing the inﬂuence of BP level. In
both studies a huge difference in the traditional risk factors (smoking,
age, cholesterol, diabetes, dislipidemia, hypertension, etc.) was
present between the two groups. Conversely, when Gerard et al.
[134] compared patients with MI and controls with the same levels of
traditional risk factors, the Trp allele frequency was higher in cases.
These ﬁndings raise the question of the competition among the
various risk factors and the signiﬁcance of the reduction of the ADD1
Trp allele in patients with MI. This reduction may be due either to a
protective effect of this allele or to a premature death of these allele
carriers. Four studies [140–143] evaluated the association between
ADD1 with or without other four candidate gene polymorphisms and
the diuretic effect on BP and on CV risk. No interaction analysis was
carried out among these genes. This type of community-based studies
rely upon general practitioner BP measurements, therapy assessed by
pharmacy record and poor control of many other confounders as
correctly admitted by the authors in their limitation section.
Therefore, the negative results of these studies may enlighten the
difﬁculties to assess the impact of genetics in medical practice.
Certainly, the genetic complexity illustrated in the previous section of
this review cannot be evaluated in this type of studies. Finally, the
same group(s) [144] evaluated the contribution of four genes (ADD1,
AGT, AGTR1 and GNB3) to the hereditability of the BP traits in a
predominantly normotensive population with a substantial portion of
hypertensives under treatment. As found in many other occasions,
this contribution of ADD1 and GNB3 is very modest, 0.3% and 0.4%,
respectively. The interactions among the four genes were not analyzed.
2.5. The pharmacogenomic strategy
At present the combination of the genetic technology with the
selective inhibition of a given genetic mechanisms both in animal
models (rodents) and humans is a promising approach able to provide
information about the impact on hypertension of a given triggering
RGN in both species. For adducin two types of drugs may be used to
apply this strategy to humans. One is hydrochlorothiazide (HCTZ) that
is not very speciﬁc but its action mechanism is certainly more suitable
to affect the cellular effects of adducin than the action mechanisms ofother drug. The other is rostafuroxin that it is discussed in another
chapter of this issue (P. Ferrari).
2.5.1. Diuretics
The bulk of the data available supports the notion that the
hypertension favouring effect of the Trp ADD1 allele is mediated by a
constitutive increase of renal Na reabsorption. Therefore, the study of
the association between the presence of the Trp allele alone, or in
combination with other gene alleles modulating its effects in Na
absorption together with the BP response to diuretics may provide
further support to this notion or dispute it.
So far 10 articles dealing with this issue either showed an
association [75,87,145,146] or its absence [142,147–151]. The differ-
ences between these two groups of studies are:
a) the former have been carried out by clinical trials in Italian
populations, with one exception [87] in relatively young newly
diagnosed and never treated patients;
b) the latter were carried out in previously treated patients with a
variable period of washout (from 0 to 30 days) without any
information of the duration of hypertension or other confounders.
In one of these studies [150], the BP basal values were taken when
the patients were switched from the previous therapy to diuretics,
without a washout period. Moreover, diuretics were given
together with lifestyle advice (reduction of Na intake) or
cholesterol-lowering agents when needed [150]. One study [149]
included 71 patients, and diuretics were given alone or “in
addition to other antihypertensive agents”. The two other studies
[142,148] were observational population-based studies aimed at
testing the inﬂuence of genetics on daily practice. Potential or real
confounders mentioned by the authors were: data collection by
self-reported questioners or from general practitioner or pharma-
cy records, uncertainties about the use of other antihypertensive
agents 2 weeks before the BP measurements or of statins or of
nonsteroidal anti-inﬂammatory drugs (NSAID), variations in the
Na intake and so on. One study [140] addresses the question
whether the diuretics could reduce the CV risk in hypertensive
carriers of the ADD1 Trp allele. This reduction was suggested by a
previous study [128] which compared patients, with the same
levels of BP, receiving diuretic treatment either for 10 years or only
3 years. The interaction was present only in the former group of
patients and the conclusion was that a long period of diuretic
treatment is needed to unmask this interaction. In the study
described by van Wieren–de Wijer [140], the analysis was carried
out by comparing two groups of patients treated for 3.1 years and
1.5 years, respectively. Clearly, considering the data of the
previous study, a negative ﬁnding could be anticipated.2.5.2. Rostafuroxin
Recently, a very selective inhibitor of ouabain and the Trp ADD1
allele both in rodents and in humans, has been developed (rostafur-
oxin) and evaluated in two clinical trials [152]. The results obtained
(M. Ferrandi, P. Ferrari and G. Valentini, manuscript in preparation)
can be summarized as follow:
a) the BP effect over placebo was measured either in never treated
patients or in previously treated patients after a washout period of
1 month before starting with the rostafuroxin administration;
b) in never treated patients a clear BP fall with rostafuroxin over
placebo was detected in carriers of the gene variants previously
predicted among the secondary end points of the study [152].
These gene variants were chosen because their inﬂuence on the EO
activity, Trp ADD1 allele and rostafuroxin effects;
c) no effect of rostafuroxin over placebo was detected in previously
treated patients carrying the alleles mentioned at point b).
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the previous therapies as suggested by a series of previous observa-
tions [153–160] or the duration of hypertension in these patients was
above the critical level that favours the development of secondary
changes. Whatever is the reason of the clear cut differences between
newly discovers and never treated on the one hand, and the
previously treated patients on the other hand, the latter are not
appropriate to study the interactions between the core RGN triggering
hypertension and the selective inhibition of some constituents of this
network.
3. Conclusions
The most important conclusion emerging from the results
illustrated above is that the ADD1 Trp allele alone may be consistently
associated to a given phenotype only in some speciﬁc conditions (i.e.,
10 independent studies in hypertensives showed its association with
increased CV risk). While in other conditions, or contexts, the ADD1
Trp allele must be associated with either genetic (other adducins,
RAAS or EO genes), environmental (Na intake) or biological factors
(gender, age, etc.) to unmask its involvement in the generation of a
clinical phenotype, such as BP, risk to develop hypertension, arterial
characteristics.
The lessons we can draw from these conclusions, which are also
consistent with many previously known pathophysiological ﬁndings,
are:
1) only the selective inhibition of the effect of ADD1 Trp allele may
unmask its real genetic effect size which could bemuch larger than
that measured effects applying the various genetic frequentistic
approaches. Therefore, the current view that in polygenic
multifactorial diseases a very large number of loci or genes may
underlie the disease must be revised. Rather one must analyze the
effect size of the various candidate genes with their appropriate
interactions and inhibitors in newly discovered and never treated
patients. For instance, the clinical impact of RAS and aldosterone
gene polymorphisms may be evaluated by coupling the genotyp-
ing with BP response to RAS and aldosterone blockers.
2) the effect size of known genes or SNPs derived from GWA study
may be affected by their transient effect in some speciﬁc phases of
hypertension.
Their detection may be limited to the subset of patients having the
speciﬁc phase at work at the time of the study. Conversely, this
phenomenon of phase-dependent gene activation may increase
the effect size of a given set of some genes (RAAS or adrenergic
genes), just because these systems may be activated in speciﬁc
phases of different types of hypertension triggered by different
RGNs. Paradoxically, the polymorphisms of these genes may be
more “replicable” in different populations than that of genes
involved in the triggering RGN. In fact the latter may require the
interaction with other genes to shift or change the function of this
RGN to produce the ﬁrst BP increase. Genetics based on the
differences among allele frequencies that do not account for this
context dependency (hypertension phase dependency) is unable
to provide the true allele effect size useful to develop an
appropriate targeted therapy.
The data so far available on the clinical settings do not allow to
propose a RGN organizedwith speciﬁc nodes and connections as it has
been presented in various experimental settings. In human complex
diseases the difﬁculties to establish precise relationship among
protein interactions, functions, and clinical symptoms are over-
whelming. We can only adopt the more realistic approach to apply
the pathophysiological connections among the different nodes or
gene products (regarding the adducin, EO or RAAS genes) that, in
various combinations, are associated to the clinical phenotypes,
discussed in this review. The hypothesis of the existence of “hubsproteins” in the RGN triggering hypertension can be tested in humans
by a selective inhibitor of the function of these proteins. This trial must
have a rigorous control of the many confounders (context) such as
natural history of hypertension and CV events, age, gender, sodium
intake, previous therapy, population ancestry, etc. The prediction is
that the same few “hubs proteins” are at work in the various tissues in
different contexts while other proteins may act as modiﬁers in some
speciﬁc contexts. In rodents this complexity may be handled with
quantitative networkmodelling tools to test RGNs, their hubs proteins
and the effect of selective inhibitors [161,162]. An example of a
successful prediction with a very selective inhibitor has been
mentioned in this review. Similar studies with others inhibitors or
drugs are in progress. It is likely that with this strategy we may “cure”
the ﬁrst phase of hypertension in the majority of patients and
moreover we may obtain solid scientiﬁc information on the function
of the proteins hit by this inhibitor. To provide the necessary
experimental support to this hypothesis the following three
approaches should be extended to the various general or hypertensive
populations:
a) to assess the risk of developing hypertension in a normotensive
population in carriers of the various triggering RGNs. The
appropriate biological, epidemiological and genetic data have to
be collected and included in the analysis. In all the four studies so
far published addressing this issue [85,95,102,121], the CV riskwas
increased in carriers of ADD1 Trp allele either alone in a population
of Japanese [95] or in combination with ACE DD in a Caucasian
[121] and Chinese populations [85] or with ADD2 T allele in
postmenopausal or Caucasian contraceptive user women [102];
b) to assess the risk of developing CV events in hypertensives or of
the related intermediate phenotypes (negative data in this second
type of risk may be expected for the previously given reasons). In
all the 10 studies, where this risk has been assessed in
hypertensives, the carriers of ADD1 Trp allele develop more CV
events than the carriers of the wild allele;
c) to study the association between the various triggering RGNs with
the phenotype response to a selective inhibitor of a speciﬁc gene (or
set of genes) effect in new discovered and never treated hyperten-
sive patients (the pharmacogenomic strategy). The advantages of
this approach consist in thepossibility to combine the gene structure
(or DNA variations) with function measured as the degree of
inhibition produced by the selective drug both in rodents and
humans. In this way species-speciﬁc differences in triggering RGNs
may also be assessed and the appropriate target for therapeutically
intervention may be detected or envisaged [163,164].References
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